209P Comparative analysis of clinician and AI decision-making in HR+/HER2- early breast cancer within routine clinical practice and clinical trial
R. Buonaiuto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Mario Giuliano(University of Naples Federico II), Pietro De Placido(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmine De Angelis(Baylor College of Medicine), Valeria Molinaro(Federico II University Hospital), Grazia Arpino(University of Naples Federico II), A. Caltavituro(Federico II University Hospital), A. Grieco(Federico II University Hospital), Claudia Martinelli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Antonio Longobardi(Federico II University Hospital), C. Criscitiello(European Institute of Oncology), Rossana Di Rienzo(University of Naples Federico II), Lucia Del Mastro(Ospedale Policlinico San Martino), Erica Pietroluongo(University of Naples Federico II), V. Cantile, Giuseppe Buono(Federico II University Hospital), F.P. Mangiacotti(Federico II University Hospital), Vincenzo Di Lauro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Gianluca Bianchini(University of Ferrara)
Cited by 0
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830